ArticleAAPS PharmSciTech2026
Development of Polymeric Microneedles with Variable Lengths for Delivery of Ebselen in Sporotrichosis.
Article in AAPS PharmSciTech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sporotrichosis is a subcutaneous mycosis of public health relevance due to the increased zoonotic transmission associated with felines. Ebselen (EB), a poorly water-soluble organic selenium compound, reacts with thiol groups of redox proteins, increases oxidative stress, and causes fungal death. Microneedles (MN) create microchannels in the skin, disrupting the stratum corneum and allowing the release and diffusion of the drug into deeper layers, potentially reaching blood capillaries. Sporotrichosis is typically treated with intravenous or oral therapies. Thus, this study developed polymeric MN for EB delivery, improving drug incorporation and dispersion while providing a minimally invasive topical alternative. A spectrophotometric method for EB analysis was validated. The molds (long and short microneedles) proved to be transparent, flexible, and easy to remove from the MN. The best formulations (F02, F09, F16, and F17) were selected. EB solubility was 0.15%. In light microscopy and scanning electron microscopy (SEM), both MN types presented well-defined and intact structures. In the compression test, the best formulation (F17) was selected in both molds. In vitro evaluation of the EB release profile from F17 showed that the long mold formulation released the drug faster than the short mold one. In vitro analysis of antifungal activity showed that the formulation containing EB induced the formation of an inhibitory halo, demonstrating antifungal activity against the fungus Sporothrix brasiliensis. Thus, the current results suggest that the MN containing EB is a promising system. Additional biological studies are required to fully assess their safety and performance in the context of sporotrichosis.
Indexed as
Identifiers
42864581What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.